Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

SeraCare – ACCURUN STI Controls

SeraCare offers a comprehensive range of molecular and serology controls, including the trusted ACCURUN® multi-marker and single-marker controls.

SeraCare controls are designed to:

  1. Validate and monitor assay performance with precision.
  2. Provide multi-marker controls for comprehensive assay validation and single-marker controls for targeted testing.
  3. Mimic real patient samples for serology and molecular PCR testing.
  4. Support compliance with quality assurance standards.

SeraCare’s range of STI controls

ACCURUN Single-Marker Positive Serology Controls

Material # Product Name Markers #Vials x Fill Size
2015-0065 ACCURUN 106, Series 1000 HIV-1 Ag 3 x 5.0 mL
2015-0066 12 x 3.5 mL
2015-0087 ACCURUN 145 CMV IgG 1 x 1.0 mL
2015-0088 ACCURUN 146 CMV IgM 1 x 1.0 mL
2015-0090 ACCURUN 155 Series 2000 Syphilis (Treponema pallidum) IgG 3 x 2.0 mL
2015-0092 ACCURUN 155 Series 5000 Syphilis (Treponema pallidum) IgG 12 x 3.5 mL
2015-0093 3 x 2.0 mL
2015-0094 ACCURUN 156 Syphilis (RPR) 3 x 1.0 mL

ACCURUN Multi-Marker Positive Serology Controls

Material # Product Name Markers #Vials x Fill Size
2000-0001 ACCURUN 1 Series 2400 Anti-HIV-1, Anti-HIV-2, Anti-HCV, Anti-HBc, Anti-HTLV-I, Anti-HTLV-II, HBsAg 12 x 3.5 mL
2000-0002 ACCURUN 1 Series 2500
2000-0008 ACCURUN 1 Series 4000 Anti-HIV-1, Anti-HIV-2, Anti-HCV, Anti-HBc, Anti-HTLV-I, Anti-HTLV-II, HBsAg, Anti-CMV 3 x 5.0 mL
2000-0010 ACCURUN 1 Series 4400 12 x 3.5 mL
2000-0018 ACCURUN 1 Series 5600 6 x 3.5 mL
2000-0023 ACCURUN 2 Series 2700 Anti-HIV-1, Anti-HIV-2, Anti-HCV, Anti-HBc, Anti-HTLV-I, Anti-HTLV-II, HBsAg, Anti-CMV, Anti-Treponema pallidum 6 x 3.5 mL
2000-0024 ACCURUN 2 Series 2700 3 x 1.0 mL
2000-0028 ACCURUN 21 Series 1000 Anti-HIV-1, Anti-HIV-2, Anti-HCV, Anti-HBc, HBsAg, Anti-HAV 6 x 3.5 mL
2000-0031 ACCURUN 21 Series 2000
2000-0032 ACCURUN 24 Confirmatory Control Anti-HIV-1, Anti-HIV-2, Anti-HCV, Anti-HTLV-I, Anti-HTLV-II 3 x 1.0 mL
2000-0034 ACCURUN 25 ToRCH IgG Anti-Toxoplasma IgG, Anti-Rubella IgG, Anti-CMV IgG, Anti-HSV IgG 3 x 1.0 mL
2000-0035 ACCURUN 26 ToRC IgM Anti-Toxoplasma IgM, Anti-Rubella IgM, Anti-CMV IgM 3 x 1.0 mL

ACCURUN Multi-Marker Positive Serology Controls

Material # Product Name Markers #Vials x Fill Size
2020-0087

ACCURUN 315 Series 150

HIV-1 RNA 10 x 1.2 mL
2020-0090 ACCURUN 315 Series 200 5 x 1.0 mL
2020-0092 ACCURUN 315 Series 400 5 x 1.0 mL
2020-0093 ACCURUN 315 Series 500 5 x 1.0 mL
2025-0068 ACCURUN 342 Series 700 Ct/Ng Nucleic Acid 10 x 1.0 mL
2020-0104 ACCURUN 345 Series 150 HBV DNA, HCV RNA, HIV-1 RNA 5 x 1.0 mL
2020-0105 5 x 4.0 mL
2025-0037 ACCURUN 372 Series 400 HPV Type 16 DNA 10 x 0.8 mL cell suspension 10 x 2.0 mL diluent
2025-0041 ACCURUN 372 Series 600 10 x 1.0 mL cell suspension 10 x 1.0 mL diluent
2025-0043 ACCURUN 378 Series 5000 20 x 4.0 mL
2025-0060 ACCURUN 381 20 x 1.0 mL

View the SeraCare ACCURUN Controls brochure

Download >

Visit the SeraCare website

Click here >

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.



Request a Quote

Request Quote

Recent Posts

Certest – VIASURE Pneumocystis jirovecii Real Time PCR Detection Kit

Pneumocystis jirovecii can cause Pneumocystis pneumonia (PCP), a life-threatening infection, especially in immunocompromised individuals such as those with HIV/AIDS, cancer patients, and organ transplant recipients….

Read full article

Biosignatures in Adult Patients with Sepsis—Critical Care Explorations (CCE), Highlighting SeptiCyte Rapid

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.We are excited to share that SeptiCyte® RAPID has been featured in the publication “The…

Read full article

Vircell 2026 Catalogues – Molecular Biology & Infectious Immunology

Vircell 2026 Catalogues* Infectious Immunology | Molecular Biology – Diagnostic Solutions for Human Infectious Diseases Discover the latest molecular biology and infectious immunology advancements with…

Read full article